Go Pro
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$15.55
-2.0%		$17.54
$15.02
▼
$40.47
$1.48B0.086,291 shs1,460 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$30.30
-0.1%		$30.12
$17.00
▼
$35.83
$1.50B1.35492,977 shs1.21 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$14.88
-4.7%		$22.84
$12.73
▼
$39.89
$1.54B0.316.36 million shs5.70 million shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$3.02
-9.9%		$3.48
$2.53
▼
$5.45
$367.74M0.51.47 million shs2.78 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
+0.06%-0.35%-6.65%-7.08%-58.57%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+1.95%+8.40%+4.12%-5.52%+62.84%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
+6.55%+19.43%-39.57%-46.38%-47.03%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
+2.45%-1.76%-4.56%+1.52%+5.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$15.55
-2.0%		$17.54
$15.02
▼
$40.47
$1.48B0.086,291 shs1,460 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$30.30
-0.1%		$30.12
$17.00
▼
$35.83
$1.50B1.35492,977 shs1.21 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$14.88
-4.7%		$22.84
$12.73
▼
$39.89
$1.54B0.316.36 million shs5.70 million shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$3.02
-9.9%		$3.48
$2.53
▼
$5.45
$367.74M0.51.47 million shs2.78 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
+0.06%-0.35%-6.65%-7.08%-58.57%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+1.95%+8.40%+4.12%-5.52%+62.84%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
+6.55%+19.43%-39.57%-46.38%-47.03%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
+2.45%-1.76%-4.56%+1.52%+5.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.20
Buy$46.43198.67% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.70
Moderate Buy$44.8648.04% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.48
Hold$34.58132.39% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.36
Hold$8.63185.60% Upside

Current Analyst Ratings Breakdown

Latest RCKT, RARE, AVBP, and AAPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$32.00 ➝ $35.00
9/18/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$18.00 ➝ $20.00
9/18/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$31.00 ➝ $32.00
9/18/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $39.00
9/18/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$33.00 ➝ $39.00
9/16/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$15.00
9/16/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$9.00
9/15/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$11.00
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$28.00 ➝ $19.00
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$43.00 ➝ $32.00
(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$82.10M17.68N/AN/A$2.04 per share7.62
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$673M2.18N/AN/A($0.83) per share-17.93
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$2.56 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$177.71MN/AN/A777.25N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.62N/AN/AN/AN/A-50.26%-46.66%11/16/2026 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$575M-$5.84N/AN/AN/A-81.79%-1,024.42%-44.40%11/3/2026 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$223.12M-$0.17N/AN/AN/AN/A-52.77%-44.92%11/5/2026 (Estimated)

Latest RCKT, RARE, AVBP, and AAPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026H1 2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A-$0.65N/A-$0.6450N/A$22.24 million
8/12/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.9873-$1.05-$0.0627-$1.05N/AN/A
8/10/2026Q2 2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$0.86$1.08+$0.22$1.08$0.22 millionN/A
8/4/2026Q2 2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.22-$0.90+$0.32-$0.90$183.08 million$214.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
1.09
1.22
1.18
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.16
14.16
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
1.73
1.56
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.05
9.24
9.24

Institutional Ownership

CompanyInstitutional Ownership
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
98.39%

Insider Ownership

CompanyInsider Ownership
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5.20%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
21.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
76793.40 millionN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
7749.31 million45.08 millionN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,37198.59 million93.46 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
202109.78 million86.39 millionOptionable

Recent News About These Companies

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
September 22 at 8:50 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/rocket-pharmaceuticals-rckt-gets-fda-alignment-on-heart-drug-trial-can-it-ease-safety-concerns-1838893/
Chardan Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
September 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RCKT/pressreleases/4635690/chardan-capital-keeps-their-buy-rating-on-rocket-pharmaceuticals-rckt/
Wedbush Reiterates "Outperform" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029634
Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Buy at Needham & Company LLC
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029643
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
September 16, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2990675/rckt-aligns-with-fda-on-completing-phase-ii-study-in-danon-disease?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2990675
Wedbush Reaffirms Outperform Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wedbush-reaffirms-outperform-rating-for-rocket-pharmaceuticals-nasdaq-rckt-2026-09-16/
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to "Buy" at Needham & Company LLC
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rocket-pharmaceuticals-nasdaq-rckt-upgraded-to-buy-at-needham-company-llc-2026-09-16/
Martin Wilson Sells 75,364 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) Stock
September 16, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rckt-insider-buying-and-selling-2026-09-16/
Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson Sells 75,364 Shares of Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-rocket-pharmaceuticals-nasdaq-rckt-general-counsel-martin-wilson-sells-75364-shares-of-stock-2026-09-15/
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946513-rocket-pharmaceuticals-inc-rckt-presents-at-morgan-stanley-24th-annual-global-healthcare
Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial
September 15, 2026  |  marketscreener.comM
Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reaffirmed at Chardan Capital
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rocket-pharmaceuticals-rckt-buy-rating-reaffirmed-at-chardan-capital-2026-09-15/
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
September 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260915485370/en/rocket-pharmaceuticals-announces-fda-alignment-on-path-to-complete-pivotal-phase-2-trial-of-rp-a501-in-danon-disease/
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of "Hold" from Brokerages
September 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31023820
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-rocket-pharmaceuticals-inc-nasdaq-rckt-given-average-recommendation-of-hold-by-analysts-2026-09-15/
Why Rocket Pharmaceuticals, Inc.’s (RCKT) Stock Is Down 5.03%
September 11, 2026  |  aaii.comA
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-rocket-pharmaceuticals-nasdaq-rckt-stock-price-crosses-below-200-day-moving-average-should-you-sell-2026-09-11/
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
September 9, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2987131/rocket-pharmaceuticals-rckt-up-6-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2987131
BlackRock Inc. Invests $33.94 Million in Rocket Pharmaceuticals, Inc. $RCKT
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-invests-3394-million-in-rocket-pharmaceuticals-inc-rckt-2026-09-02/
Chardan Capital Reiterates "Buy" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-chardan-capital-reiterates-buy-rating-for-rocket-pharmaceuticals-nasdaq-rckt-2026-09-01/
Ieq Capital LLC Invests $1.51 Million in Rocket Pharmaceuticals, Inc. $RCKT
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ieq-capital-llc-invests-151-million-in-rocket-pharmaceuticals-inc-rckt-2026-08-27/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Composite image showing rare earth ore mining, processed metal materials in a factory, and nuclear power plant cooling towers.
3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
By Chris Markoch | September 10, 2026
LightPath Technologies logo beside an optical lens, with a cleanroom worker and military jet blurred in the background.
LightPath’s Defense Pivot Could Send Shares Higher
By Thomas Hughes | September 15, 2026
Two piles of rare earth mineral powder and small metal components displayed in a glass dish in a laboratory setting.
Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership
By Nathan Reiff | September 23, 2026
Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$15.54 -0.33 (-2.05%)
Closing price 03:57 PM Eastern
Extended Trading
$15.52 -0.02 (-0.13%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$30.30 -0.02 (-0.07%)
Closing price 04:00 PM Eastern
Extended Trading
$30.27 -0.03 (-0.10%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.88 -0.73 (-4.68%)
Closing price 04:00 PM Eastern
Extended Trading
$14.91 +0.03 (+0.23%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$3.02 -0.33 (-9.85%)
Closing price 04:00 PM Eastern
Extended Trading
$3.05 +0.03 (+0.99%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas